Search

Zai Lab Ltd ADR

Suletud

SektorTervishoid

25.09 1.33

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.71

Max

25.23

Põhinäitajad

By Trading Economics

Sissetulek

191K

-51M

Müük

6.7M

106M

Aktsiakasum

-0.46

Kasumimarginaal

-47.808

Töötajad

1,784

EBITDA

-2.1M

-46M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+55.41% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

951M

3B

Eelmine avamishind

23.76

Eelmine sulgemishind

25.09

Uudiste sentiment

By Acuity

100%

0%

313 / 340 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. okt 2026, 23:51 UTC

News

Brookdale Senior Living reported a 130 basis point increase in occupancy to 83.1% for Q3 2026, but shares declined in after-market hours.

8. okt 2026, 23:46 UTC

News

KKR shares are advancing as Refresco considers an IPO potentially valuing the firm at over $10 billion; KKR Capital Corp announced a $0.44 quarterly distribution.

8. okt 2026, 23:42 UTC

Social Media
News

Ginkgo Bioworks to provide in-kind access to its Boston lab for the National Science Foundation’s $1.5 billion X-Labs program supporting independent research teams.

8. okt 2026, 23:30 UTC

News

Pacira Biosciences shares declined in after-market hours following a downgrade by Jefferies to Hold, with a price target set at $36.

8. okt 2026, 23:30 UTC

News

Chipotle Mexican Grill Inc's stock advanced amid reports that Starbucks is considering a potential acquisition, with advisers enlisted for what could be a historic deal.

8. okt 2026, 23:30 UTC

News

Walt Disney Company is in talks with rival studios about its Infinity Vision format to compete with Imax, despite shares trading lower.

8. okt 2026, 23:20 UTC

News

Immersion Corp CEO Eric Singer acquired 41k shares for approximately $292.8K on October 7, according to a regulatory filing.

8. okt 2026, 23:15 UTC

News

Cleveland-Cliffs shares advanced in after-market trading as CEO Lourenco Goncalves discussed potential steelworker recalls tied to a Canada-U.S. trade deal.

8. okt 2026, 23:11 UTC

News

Abcellera Biologics to present Phase 1/2 data for investigational drug ABCL635 at The Menopause Society's Annual Meeting in October.

8. okt 2026, 23:10 UTC

News

Citigroup downgraded Universal Display Corp to Sell and lowered its price target to $71, contributing to investor caution ahead of earnings.

8. okt 2026, 23:10 UTC

News

JP Morgan maintains Underweight rating on Kennametal Inc and lowers price target to $30, contributing to a decline in the stock during after-market hours.

8. okt 2026, 23:10 UTC

News

Barclays initiates Equalweight coverage with $554 target.

8. okt 2026, 23:05 UTC

News

Boeing Co shares gained in after-market hours after Barclays initiated coverage with an Overweight rating and a price target of $300.

8. okt 2026, 23:05 UTC

News
Correlated Moves

HubSpot Inc. declines in after-market trading following a downgrade from JP Morgan, which lowered its rating to Neutral and price target to $240.

8. okt 2026, 23:05 UTC

News

Barclays initiates coverage on Joby Aviation with an Underweight rating and a price target of $4.00, contributing to recent declines in after-market trading.

8. okt 2026, 23:05 UTC

News

USD/CZK declines modestly following U.S. jobless claims data showing initial claims fell to 197k, indicating ongoing labor market strength amid broader economic concerns.

8. okt 2026, 23:01 UTC

Social Media
News
Event

Park Aerospace Corp reported second-quarter net sales of $20.79 million and net earnings of $4.53 million, exceeding expectations amid strong demand in aerospace sectors.

8. okt 2026, 23:01 UTC

News

Over 69% of Medicare Advantage members in high-rated plans for 2027

8. okt 2026, 23:01 UTC

Social Media
News

Alignment Healthcare's stock declined sharply after a downgrade of its largest California contract's Medicare Advantage Star Rating from 4 stars to 3.5 stars.

8. okt 2026, 23:01 UTC

News

JP Morgan maintains Neutral rating on Deere & Co, raises price target to $625, reflecting a cautious outlook on the company's performance.

8. okt 2026, 23:01 UTC

News

Moomoo launches 24/7 account deposits via Apple Pay and Google Pay through a partnership with Visa and Checkout.com to enhance user funding capabilities.

8. okt 2026, 23:01 UTC

News

Citigroup downgraded Xerox Holdings Corp to Sell and lowered its price target to $2.50, citing concerns over performance and market position.

8. okt 2026, 23:01 UTC

News
Social Media
Correlated Moves

Verizon shares fell sharply in after-hours trading, attributed to competitive pressures from SpaceX's spectrum license acquisition and AT&T's notable drop.

8. okt 2026, 23:01 UTC

Social Media
News

American Express faces regulatory scrutiny and agrees to a $350 million penalty for anti-money laundering deficiencies related to $13 billion in suspected activity.

8. okt 2026, 23:01 UTC

News

USD/ZAR declines as U.S. jobless claims show a four-week average of 198k, slightly down from 200.5k.

8. okt 2026, 23:01 UTC

Social Media
News

RTX Corp awarded a five-year contract worth up to $6.3 billion for Standard Missile-3 Block IB interceptors, announced by Raytheon.

8. okt 2026, 23:01 UTC

News

Humana's largest Medicare Advantage contract improved to 4 stars in the 2027 ratings, reinstating eligibility for federal quality bonus payments.

8. okt 2026, 23:01 UTC

News

DICK'S Sporting Goods faces a class action lawsuit for failing to disclose material information, with Kahn Swick & Foti, LLC urging affected shareholders to file by November 3, 2026.

8. okt 2026, 23:00 UTC

News

Citigroup maintains a Buy rating on Arista Networks and raises its price target to $248, according to a report published today.

8. okt 2026, 22:50 UTC

Social Media
News

Starbucks explored a potential acquisition of Chipotle, valued at $41 billion, but analysts express skepticism about the strategic rationale amid ongoing turnaround efforts.

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

55.41% tõus

12 kuu keskmine prognoos

Keskmine 39.333 USD  55.41%

Kõrge 45 USD

Madal 36 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

313 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.